Literature DB >> 17996525

Depression, anxiety, and quality of life in patients with obstructive hypertrophic cardiomyopathy three months after alcohol septal ablation.

Eva R Serber1, Samuel F Sears, Christopher D Nielsen, William H Spencer, Karen M Smith.   

Abstract

Patients with obstructive hypertrophic cardiomyopathy are presumed to have poor quality of life (QOL) and distress related to their cardiac symptoms and functional limitations. Alcohol septal ablation (ASA) is designed to improve heart function and reduce cardiac symptoms. The purpose of this study was to examine psychosocial factors and QOL in patients with obstructive hypertrophic cardiomyopathy before and 3 months after ASA. Twenty-two adult participants (mean age 57 +/- 14 years, 59% women, 100% Caucasian, 67% married) were recruited during their initial evaluations or scheduled index hospitalizations for ASA. Psychosocial and medical measures were collected before and 3 months after ASA. The results indicated that before ASA, 57% of patients reported clinically relevant levels of depression (Center for Epidemiologic Studies Depression Scale score >16), symptoms of anxiety, and reduced QOL. Repeated-measures analyses of variance revealed that ASA is an effective procedure in reducing disease severity (i.e., peak left ventricular outflow tract gradient, septal thickness, posterior wall thickness) (p = 0.001 to 0.05), depression (p = 0.005), and anxiety (p = 0.029) and improving cardiac-specific QOL (p < 0.001) and generic physical health-related QOL (p = 0.009). Changes in satisfaction with life, optimism, and generic mental health-related QOL were not significant (p = 0.143 to 0.899). In conclusion, significant psychological distress and compromised well-being were present in this sample of pre-ASA patients with obstructive hypertrophic cardiomyopathy. After ASA, significant reductions in psychological distress and improvements in well-being and echocardiographic parameters indicating disease severity were demonstrated. These results suggest that patients perceived broad health benefits from ASA in short-term follow-up.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17996525     DOI: 10.1016/j.amjcard.2007.06.063

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  6 in total

1.  Depression in patients with hypertrophic cardiomyopathy: is there any relation with the risk factors for sudden death?

Authors:  Artemis Igoumenou; Giorgos Alevizopoulos; Aris Anastasakis; Errika Stavrakaki; Pavlos Toutouzas; Christodoulos Stefanadis
Journal:  Heart Asia       Date:  2012-01-01

2.  Anxiety Predicts Poor Prognosis in Patients With Hypertrophic Cardiomyopathy.

Authors:  Chao-Jie He; Chang-Lin Zhai; Shao-Dai Huang; Hong-Yan Fan; Ye-Zhou Qian; Chun-Yan Zhu; Hui-Lin Hu
Journal:  Front Cardiovasc Med       Date:  2022-05-19

3.  Cardiac sympathetic denervation and mental health.

Authors:  Sahib S Khalsa; Ashley N Clausen; Leila Shahabi; Julie Sorg; Sarah E Gonzalez; Bruce Naliboff; Kalyanam Shivkumar; Olujimi A Ajijola
Journal:  Auton Neurosci       Date:  2021-02-14       Impact factor: 3.145

4.  Isobaric Tags for Relative and Absolute Quantitation Identification of Blood Proteins Relevant to Paroxetine Response in Patients With Major Depressive Disorder.

Authors:  Chin-Chuen Lin; Hung Su; Jentaie Shiea; Tiao-Lai Huang
Journal:  Front Psychiatry       Date:  2022-04-18       Impact factor: 5.435

5.  Health-related quality of life in hypertrophic cardiomyopathy patients with implantable defibrillators.

Authors:  Peter Magnusson; Stellan Mörner; Fredrik Gadler; Jan Karlsson
Journal:  Health Qual Life Outcomes       Date:  2016-04-14       Impact factor: 3.186

6.  Quality of life status determinants in hypertrophic cardiomyopathy as evaluated by the Kansas City Cardiomyopathy Questionnaire.

Authors:  Razvan Capota; Sebastian Militaru; Alin Alexandru Ionescu; Monica Rosca; Cristian Baicus; Bogdan Alexandru Popescu; Ruxandra Jurcut
Journal:  Health Qual Life Outcomes       Date:  2020-10-30       Impact factor: 3.186

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.